Called Enflonsia and developed by Merck & Co., the drug is an antibody intended to prevent illness from RSV, which can be particularly severe in young children.

Merck's monoclonal antibody, called clesrovimab and branded as Enflonsia, is the first and only preventive shot that can be administered as a single dose regardless of birth weight in healthy pre ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

Merck MRK is thriving on new products and pipeline candidates to drive its long-term growth. The company has built a substantial portfolio of new pipeline candidates and has made meaningful regulatory ...

Robert F. Kennedy Jr.’s vaccine advisory committee recommended Merck & Co.’s shot to prevent newborns from getting RSV, alleviating some concerns that the new Department of Health and ...